Global Benign Prostate Hyperplasia (BPH) Market, Size, Share, Opportunities and Forecast, 2020-2027

Global Benign Prostate Hyperplasia (BPH) Market is segmented By Drug Type (Alpha Blocker, 5-Alpha Reductase Inhibitors), By Surgery (TURP, TUMT, TUNA, Others), By End User (Hospitals, Home Care, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Share, Size, Outlook, and Opportunity Analysis, 2020-2027

Market Overview

The Global Benign Prostate Hyperplasia (BPH) Market is expected to grow at a CAGR of ~ 6% during the forecasting period (2020-2027).

BPH (benign prostatic hyperplasia) is a urological disease marked by the non-cancerous proliferation of prostate gland cells. The gland enlarges as a result of this disease, rubbing against the urethra and limiting urine flow. Aging, hormonal imbalances, and irregular cell growth are also related to this disease. BPH is characterized by excessive urination, trouble starting urine, a poor urinary tract, and the inability to drain the urinary bladder. Men with mild to moderate BPH are currently treated with drugs.

Source: DataM Intelligence Analysis (2019)

Market Dynamics

The growth in the male geriatric population is driving the global benign prostatic hyperplasia therapeutics industry. Other factors driving demand development include increased awareness of prostate cancer and other urological diseases, as well as a rise in the number of patients with benign prostatic hyperplasia around the world.

Rise in Geriatric Population

BPH (benign prostatic hyperplasia) is becoming more commonly recognised as a growing health concern among elderly men. The magnitude of the problem is predicted to multiply in the coming years as the number of elderly men increases. According to a survey released by the United States Census Bureau in 2018, the number of people aged 65 and over in the United States is projected to grow significantly between 2016 and 2060. By 2030, one of every five Americans will be 65 or older, accounting for 78.0 million people out of the current population. By the age of 60, nearly half of men have histopathologic BPH, and by the age of 85, 90% of men have it. BPH signs are said to affect 30 million men globally and 14 million men in the United States.

Side-effects associated with BPH medications

Although both medications and surgery can be used to treat BPH, both have serious side effects. Alpha-blockers, 5-ARIs (5-alpha reductase inhibitors), and other drug groups are widely used to treat BPH. Dizziness, orthostatic hypotension, retrograde ejaculation, and rhinitis are all typical side effects of alpha-blockers. Dizziness and orthostatic hypotension are most frequent in the elderly, and they can lead to severe problems such as falls and fractures. The complications associated with the use of drugs is a key factor expected to curtail growth of the global market over the forecast period.

COVID-19 Impact Analysis

The COVID-19 epidemic is projected to have a major effect on the BPH care industry. Elective surgeries with benign pathology were advised to be deferred until the burden on the medical system from COVID-19 lessened, so hospitals will face a tremendous need for services to tackle a potential rise in COVID-19 incidents. Surgical operations such as TURP, HoLEP, ThuLEP, and PVP had to be delayed as a result.

Benign Prostate Hyperplasia (BPH) Market Segment Analysis

Based on the drug type, the Benign Prostate Hyperplasia (BPH) market has been classified into alpha blocker and 5-alpha reductase inhibitors.

Alpha blocker segment is projected to be the dominated segment in the market during the forecast period.

Alpha blocker dominated the global market in 2019, owing to the strong preference of alpha blocker medications and its used in a wide number of countries. Whereas, the 5-alpha reductase inhibitors is expected to present a considerable growth in the near future.

The global Benign Prostate Hyperplasia (BPH) is segmented on the basis of surgery, which includes TURP, TUMT, TUNA and Others.

TURP is expected to dominate the Benign Prostate Hyperplasia (BPH) market.

TURP held the dominant position in the global market during the forecast period owing to surge in use of TURP surgery globally. Prostate transurethral resection is a urological technique that is used to treat benign prostatic hyperplasia (BPH). It includes visualizing the prostate through the urethra and cutting tissue with electrocautery or sharp dissection. As a result, the demand is expected to increase as TURP becomes more common. Moreover, the TURP is expected to project a considerable CAGR during the forecast period.

Source: DataM Intelligence Analysis (2019)

Benign Prostate Hyperplasia (BPH) is segmented on the basis of end user, which includes hospitals, home care and others.

Home Care is expected to dominate the Benign Prostate Hyperplasia (BPH) market.

Home Care held the dominant position in the global market during the forecast period. The majority of patients are given drugs instead of surgery. Patients are recommended to continue taking their medications for a few weeks after surgery. As a result, the market is driven by home treatment, compared to hospital services. Moreover, the demand is expected to increase with rising preference for home care settings. Therefore, the homecare is expected to project a considerable CAGR during the forecast period.

Benign Prostate Hyperplasia (BPH) Market Geographical Analysis

Based on geography, the study analyzes the Benign Prostate Hyperplasia (BPH) market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

North America is expected to dominate the global Benign Prostate Hyperplasia (BPH) market

North America is held a dominant position in the global Benign Prostate Hyperplasia (BPH) market in 2019. In North America, the U.S. is expected to represent considerable growth during the forecast period. High prevalence of BPH and other associated lower urinary tract symptoms. Several studies over the past decade have shown that a large number of men in the U.S., aged 45 to 80, suffer from lower urinary tract symptoms, with the bulk of them experiencing BPH symptoms, which results in huge market for Benign Prostate Hyperplasia (BPH). Moreover, Europe is expected to represent significant growth in terms of value during the forecast period. Significant investment in R&D and advanced product development is expected to propel the market growth across the region. Benign Prostate Hyperplasia (BPH) market for Asia Pacific is expected to observe rapid growth over the forecast period, backed by the large population base, especially in India and China. Moreover, rise in health care expenditure and rapidly increasing prevalence of various urologic diseases is expected to augment the growth the Asia Pacific Benign Prostate Hyperplasia (BPH) market.

Benign Prostate Hyperplasia (BPH) Market Competitive Landscape

The Benign Prostate Hyperplasia (BPH) market is highly competitive, owing to the presence of big medical companies. The key players which are contributing to the growth of the global market include Endo International plc, KARL STORZ GMBH & CO.KG, Lumenis, Olympus Corporation., Urologix Inc., Boston Scientific Corporation, Coloplast A/S, Lisa Laser, Medifocus Inc, Neotract Inc, among others. The major players are adopting new product launch and expansion strategies for global growth in the Benign Prostate Hyperplasia (BPH) market.  

Holmium Laser Vaporization of the Prostate (Lumenis):

Holmium Laser Vaporization of the Prostate (HoLVP) is a BPH treatment option that is both safe and effective, providing immediate symptom relief with few side effects. Without inducing deeper thermal injury, coagulation necrosis, or collateral damage, the holmium laser penetrates only enough to accurately and rapidly vaporise tissue. HoLVP is a non-invasive, outpatient treatment that provides for a rapid recovery and return to normal life.

Drug Type Portfolio: The Company's portfolio comprises urology treatment solutions such as HoLEP, vaporization among others.

Why Purchase the Report?

Visualize the Benign Prostate Hyperplasia (BPH) market segmentation composition by drug type, surgery, end user and region, highlighting the critical commercial assets and players.

Identify commercial opportunities in the Benign Prostate Hyperplasia (BPH) market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of Benign Prostate Hyperplasia (BPH) market - level 3 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Drug Type mapping in excel for the key products of all major market players

The global Benign Prostate Hyperplasia (BPH) market report would provide access to an approx. 54 market data table, 53 figures and 221 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers